<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="793" width="595">
	<fontspec id="0" size="9" family="AFJGGC+AdvTT99c4c969" color="#231f20"/>
	<fontspec id="1" size="10" family="AFJGGD+AdvTT86d47313" color="#231f20"/>
	<fontspec id="2" size="7" family="AFJGGD+AdvTT86d47313" color="#231f20"/>
	<fontspec id="3" size="10" family="AFJHJD+AdvTT8861b38f.I" color="#231f20"/>
	<fontspec id="4" size="10" family="AFJGHF+AdvTT86d47313+03" color="#231f20"/>
	<fontspec id="5" size="10" family="AFJGHE+AdvTT86d47313+20" color="#231f20"/>
	<fontspec id="6" size="8" family="AFJGEO+AdvTTaf7f9f4f.B" color="#231f20"/>
	<fontspec id="7" size="8" family="AFJGGC+AdvTT99c4c969" color="#231f20"/>
	<fontspec id="8" size="8" family="AFJGFA+AdvTTb5929f4c" color="#231f20"/>
	<fontspec id="9" size="8" family="AFJGEP+AdvTTe45e47d2" color="#231f20"/>
	<fontspec id="10" size="8" family="AFJHEC+AdvTT7329fd89.I" color="#231f20"/>
<text top="90" left="57" width="52" height="8" font="0">Study design</text>
<text top="102" left="57" width="234" height="9" font="1">This was a cross sectional study with two visits within</text>
<text top="114" left="57" width="234" height="9" font="1">3 weeks. In visit 1, all subjects completed clinical ques-</text>
<text top="126" left="57" width="234" height="9" font="1">tionnaires, provided informed consent, underwent a</text>
<text top="138" left="57" width="234" height="9" font="1">physical examination and had allergy skin tests. At this</text>
<text top="150" left="57" width="234" height="9" font="1">time, subjects also performed a methacholine inhalation</text>
<text top="162" left="57" width="234" height="9" font="1">test, had a urine test for pregnancy (where applicable)</text>
<text top="174" left="57" width="234" height="9" font="1">and subjects in the CA group were provided with salme-</text>
<text top="186" left="57" width="234" height="9" font="1">terol and salbutamol. At visit 2, spirometry was per-</text>
<text top="198" left="57" width="234" height="9" font="1">formed including bronchodilator reversibility, sputum</text>
<text top="210" left="57" width="234" height="9" font="1">and blood samples were taken for multiple analyses (see</text>
<text top="222" left="57" width="234" height="9" font="1">below). Remaining salmeterol and salbutamol were col-</text>
<text top="234" left="57" width="155" height="9" font="1">lected from subjects in the CA group.</text>
<text top="246" left="65" width="226" height="9" font="1">Inhaled corticosteroid medication was discontinued in</text>
<text top="258" left="57" width="234" height="9" font="1">the CA group 2 weeks prior to subject testing and sam-</text>
<text top="270" left="57" width="234" height="9" font="1">ple collection. At the time inhaled steroid was discontin-</text>
<text top="282" left="57" width="234" height="9" font="1">ued, 2 puffs bid salmeterol was provided. Forty eight</text>
<text top="294" left="57" width="234" height="9" font="1">hours before samples were taken, salmeterol was</text>
<text top="306" left="57" width="234" height="9" font="1">stopped and substituted with salbutamol 2 inhalations</text>
<text top="318" left="57" width="234" height="9" font="1">qid. Salbutamol was stopped at least 6 hours before</text>
<text top="330" left="57" width="234" height="9" font="1">blood samples were taken. Laboratory testing was per-</text>
<text top="342" left="57" width="234" height="9" font="1">formed simultaneously on three (matched) subjects, one</text>
<text top="354" left="57" width="234" height="9" font="1">from each group. Laboratory personnel performing the</text>
<text top="366" left="57" width="234" height="9" font="1">tests were not informed of the groups to which each</text>
<text top="378" left="57" width="71" height="9" font="1">subject belonged.</text>
<text top="402" left="57" width="45" height="8" font="0">Procedures</text>
<text top="414" left="57" width="234" height="9" font="1">Routine physical examination, questionnaire and clinical</text>
<text top="426" left="57" width="234" height="9" font="1">tests were performed according to standard protocols.</text>
<text top="438" left="57" width="200" height="9" font="1">Spirometry included measurement of FVC, FEV</text>
<text top="442" left="257" width="4" height="6" font="2">1</text>
<text top="438" left="260" width="23" height="9" font="1">, FEV</text>
<text top="442" left="283" width="4" height="6" font="2">1</text>
<text top="438" left="287" width="4" height="9" font="1">/</text>
<text top="450" left="57" width="234" height="9" font="1">VC and methacholine challenge tests. Blood counts</text>
<text top="462" left="57" width="149" height="9" font="1">included a manual eosinophil count.</text>
<text top="486" left="57" width="158" height="8" font="0">Sputum cell induction and examination</text>
<text top="498" left="57" width="234" height="9" font="1">Sputum was induced with an aerosol of inhaled hyper-</text>
<text top="510" left="57" width="210" height="9" font="1">tonic saline by a modification of the method of Pin</text>
<text top="510" left="270" width="20" height="10" font="3">et al.</text>
<text top="522" left="57" width="218" height="9" font="1"><a href="">[32] </a>after pretreatment with inhaled Salbutamol 200</text>
<text top="519" left="278" width="5" height="13" font="4">μ</text>
<text top="522" left="284" width="7" height="9" font="1">g.</text>
<text top="534" left="57" width="234" height="9" font="1">The modification consisted of inhaling the hypertonic</text>
<text top="546" left="57" width="234" height="9" font="1">saline in concentrations of 3, 4 and 5% each for 7 min-</text>
<text top="558" left="57" width="234" height="9" font="1">utes. Sputum examination followed the method of Pizzi-</text>
<text top="570" left="57" width="20" height="9" font="1">chini</text>
<text top="570" left="83" width="23" height="10" font="3">et al.</text>
<text top="570" left="112" width="179" height="9" font="1"><a href="">[33]</a>. Sputum mediator assessments were</text>
<text top="582" left="57" width="234" height="9" font="1">performed using routine protocols. The concentration of</text>
<text top="594" left="57" width="234" height="9" font="1">eosinophil cationic protein (ECP) was determined using</text>
<text top="606" left="57" width="234" height="9" font="1">a sensitive radioimmunoassay (Kabi-Pharmacia Diagnos-</text>
<text top="618" left="57" width="234" height="9" font="1">tics AB, Uppsala, Sweden). Fibrinogen was measured</text>
<text top="630" left="57" width="35" height="9" font="1">using an</text>
<text top="627" left="95" width="4" height="13" font="5">“</text>
<text top="630" left="99" width="35" height="9" font="1">in house</text>
<text top="627" left="134" width="4" height="13" font="5">”</text>
<text top="630" left="141" width="149" height="9" font="1">ELISA assay which employed rabbit</text>
<text top="642" left="57" width="234" height="9" font="1">anti-fibrinogen antibody (Dako# A080). Cytokines were</text>
<text top="654" left="57" width="234" height="9" font="1">assayed by ELISA (IL-5 using Biotrak kit, Amersham,</text>
<text top="666" left="57" width="57" height="9" font="1">UK and TNF-</text>
<text top="663" left="114" width="5" height="13" font="4">α</text>
<text top="666" left="122" width="9" height="9" font="1">by</text>
<text top="663" left="135" width="4" height="13" font="5">“</text>
<text top="666" left="138" width="35" height="9" font="1">in house</text>
<text top="663" left="173" width="4" height="13" font="5">”</text>
<text top="666" left="180" width="32" height="9" font="1">ELISA).</text>
<text top="690" left="57" width="138" height="8" font="0">Peripheral blood cytokine analysis</text>
<text top="702" left="57" width="234" height="9" font="1">Peripheral blood mononuclear cells (PBMC) were iso-</text>
<text top="714" left="57" width="234" height="9" font="1">lated from the blood of each subject. Matched triplets</text>
<text top="726" left="57" width="234" height="9" font="1">which included one subject from each group were</text>
<text top="90" left="305" width="234" height="9" font="1">sampled and assayed in parallel. Short term cultures of</text>
<text top="102" left="305" width="234" height="9" font="1">PBMC were established for 24 or 72 hours in the pres-</text>
<text top="114" left="305" width="234" height="9" font="1">ence or absence of a series of stimulants. These included</text>
<text top="126" left="305" width="85" height="9" font="1">anti-CD3 antibody 1</text>
<text top="123" left="393" width="5" height="13" font="4">μ</text>
<text top="126" left="398" width="140" height="9" font="1">g/ml (OKT3, Cedarlane , Burling-</text>
<text top="138" left="305" width="68" height="9" font="1">ton, Ont), killed</text>
<text top="138" left="377" width="92" height="10" font="3">Staphylococcus aureus</text>
<text top="138" left="474" width="65" height="9" font="1">Cowan strain 1</text>
<text top="150" left="305" width="207" height="9" font="1">bacteria (SAC) 0.07% w/v (Sigma, St Louis, Mo).</text>
<text top="150" left="516" width="23" height="10" font="3">E-coli</text>
<text top="162" left="305" width="91" height="9" font="1">derived LPS (Sigma) 5</text>
<text top="159" left="399" width="5" height="13" font="4">μ</text>
<text top="162" left="404" width="104" height="9" font="1">g/ml, Tetanus toxoid (0.1</text>
<text top="159" left="511" width="5" height="13" font="4">μ</text>
<text top="162" left="516" width="22" height="9" font="1">g/ml)</text>
<text top="174" left="305" width="234" height="9" font="1">and a combination of phorbol ester PDBu (Sigma)</text>
<text top="186" left="305" width="13" height="9" font="1">(10</text>
<text top="184" left="318" width="6" height="6" font="2">-6</text>
<text top="186" left="332" width="206" height="9" font="1">M) and Calcium ionophore A23187 (Sigma)</text>
<text top="198" left="305" width="13" height="9" font="1">(10</text>
<text top="196" left="318" width="6" height="6" font="2">-7</text>
<text top="198" left="328" width="211" height="9" font="1">M). The concentrations and timing of these stim-</text>
<text top="210" left="305" width="216" height="9" font="1">uli were selected on the basis of pilot experiments.</text>
<text top="222" left="313" width="226" height="9" font="1">The cytokine content of cell free supernatants, was</text>
<text top="234" left="305" width="228" height="9" font="1">assessed using ELISA kits with the exception of TNF-</text>
<text top="231" left="533" width="5" height="13" font="4">α</text>
<text top="246" left="305" width="184" height="9" font="1">which was assessed using a well validated</text>
<text top="243" left="494" width="4" height="13" font="5">“</text>
<text top="246" left="498" width="37" height="9" font="1">in house</text>
<text top="243" left="535" width="4" height="13" font="5">”</text>
<text top="258" left="305" width="234" height="9" font="1">ELISA. The cytokine kits employed were: IL-4- Biotrak</text>
<text top="270" left="305" width="234" height="9" font="1">RPN 2753, IL-5- Biotrak RPN2761, IL-6 Biotrak RPN</text>
<text top="282" left="305" width="234" height="9" font="1">2754, IL-10 Biotrak RPN 2755, IL-12- Biotrak RPN</text>
<text top="294" left="305" width="234" height="9" font="1">2765, GM-CSF Biotrak RPN 2757. All of these kits were</text>
<text top="306" left="305" width="207" height="9" font="1">obtained from Amersham (Toronto, ON, Canada).</text>
<text top="342" left="305" width="156" height="8" font="0">Flow cytometric protocols and analysis</text>
<text top="354" left="305" width="234" height="9" font="1">Panels of antibodies were employed in 2 and 3 colour ana-</text>
<text top="366" left="305" width="234" height="9" font="1">lysis protocols to identify and calculate frequencies of T-</text>
<text top="378" left="305" width="234" height="9" font="1">cell subsets, B cells, monocytes and subsets of these cells</text>
<text top="390" left="305" width="234" height="9" font="1">expressing important functional markers. A complete</text>
<text top="402" left="305" width="234" height="9" font="1">listing of B and T lymphocyte, and monocyte phenotypes</text>
<text top="414" left="305" width="234" height="9" font="1">analysed by flow cytometry are listed in Figure <a href="">1. </a>All</text>
<text top="426" left="305" width="234" height="9" font="1">staining was done in whole blood with subsequent fixation</text>
<text top="438" left="305" width="234" height="9" font="1">and wash. Flourescent labelled antibodies against CD3,</text>
<text top="450" left="305" width="234" height="9" font="1">CD4, CD8, CD14, HLADR, CD45RO CD45RA, CD40</text>
<text top="462" left="305" width="234" height="9" font="1">and CD23 were purchased from Becton Dickinson</text>
<text top="474" left="305" width="234" height="9" font="1">Canada (Mississuaga., Ontario). Antibody to CD40 ligand</text>
<text top="671" left="311" width="29" height="7" font="6">Figure 1</text>
<text top="671" left="343" width="175" height="7" font="7">Blood Cell Phenotypes defined for analysis of flow</text>
<text top="681" left="311" width="56" height="7" font="7">cytometric data.</text>
<text top="681" left="369" width="152" height="7" font="8">Major lymphocyte subsets are reported as % of</text>
<text top="691" left="311" width="214" height="7" font="8">total lymphocytes. Activated or functional lymphocyte subsets are</text>
<text top="701" left="311" width="216" height="7" font="8">reported as % of each lymphocyte type. Expression of functional B</text>
<text top="711" left="311" width="213" height="7" font="8">or monocyte surface markers are reported as median fluorescence</text>
<text top="721" left="311" width="28" height="7" font="8">intensity.</text>
<text top="35" left="57" width="35" height="7" font="9">Waserman</text>
<text top="33" left="94" width="145" height="9" font="10">et al. Allergy, Asthma &amp; Clinical Immunology</text>
<text top="35" left="241" width="18" height="7" font="9">2012,</text>
<text top="35" left="261" width="4" height="7" font="6">8</text>
<text top="35" left="266" width="10" height="7" font="9">:16</text>
<text top="35" left="496" width="43" height="7" font="9">Page 3 of 14</text>
<text top="45" left="57" width="145" height="7" font="9">http://www.aacijournal.com/content/8/1/16</text>
</page>
</pdf2xml>
